It appears that the biopharmaceutical industry's innovation engine is back on track and making up for its poor return on research investments last year when only 22 new molecular entities (NMEs) received the FDA's Center for Drug Evaluation and Research (CDER) green light, the fewest number for five years. (See BioWorld Insight, Dec. 27, 2016.)